There are limited national and international studies into the burden of<unk> , made more difficult by a non-standardized diagnostic criteria. Estimates of between 0.5 and 3.5% have been made for<unk>  burden in asthma, and 1–17.7% in CF. Five national cohorts, detecting<unk>  prevalence in asthma (based on GINA estimates), were used in a recent meta-analysis to produce an estimate of the global burden of<unk>  complicating asthma. From 193 million asthma sufferers worldwide,<unk>  prevalence in asthma is estimated between the extremes of 1.35–6.77 million sufferers, using 0.7–3.5% attrition rates. A compromise at 2.5% attrition has also been proposed, placing global burden at around 4.8 million people affected. The Eastern Mediterranean region had the lowest estimated prevalence, with a predicted case burden of 351,000; collectively, the Americas had the highest predicted burden at 1,461,000 cases. These are likely underestimates of total prevalence, given the exclusion of CF patients and children from the study, as well as diagnostic testing being limited in less developed regions.
Allergic bronchopulmonary aspergillosis
Chronic pulmonary aspergillosis
Tuberculosis
Miliary tuberculosis
Fungal pneumonia
Primary pulmonary coccidioidomycosis
Cryptogenic organizing pneumonia
Atypical pneumonia